Skip to main content

Table 4 Independent association of use and dose of long-acting ESA with Hb level by multiple linear regression analysis

From: Effect of long-acting erythropoiesis-stimulating agents on hemoglobin levels at the initiation of dialysis

Model Adjustment   Regression coefficient 95 % CI P
Model 1a Unadjusted Long-acting ESA 0.204 0.515 1.02 .000
Dose of ESA/1000 units 0.024 −0.007 0.014 .483
Model 2b Age, sex, diabetes, BMI, SBP, vascular access, nephrologists care, CTR Long-acting ESA 0.191 0.427 0.976 .000
Dose of ESA/1000 units −0.019 −0.014 0.008 .613
Model 3c Model 2 + albumin, CRP Long-acting ESA 0.169 0.341 0.912 .000
Dose of ESA/1000 units −0.013 −0.013 0.009 .721
Model 4d Model 2 + TC, TG,HDL-C, Glu Long-acting ESA 0.196 0.41 1.039 .000
Dose of ESA/1000 units −0.023 −0.017 0.01 .588
Model 5e Model 2 + Ca, P, iPTH, vitamin D long-acting ESA 0.186 0.388 0.948 .000
Dose of ESA/1000 units −0.022 −0.015 0.008 .570
Model 6f Model 2 + Fe, TIBC, ferritin, iron tx Long-acting ESA 0.168 0.275 0.848 .000
Dose of ESA/1000 units −0.029 −0.018 0.009 .503
Model 7g Model 2 + ACEI/ARB, AST-120 Long-acting ESA 0.188 0.411 0.962 .000
Dose of ESA/1000 units −0.016 −0.014 0.009 .683
Model 8h All Long-acting ESA 0.155 0.176 0.858 .003
Dose of ESA/1000 units −0.029 −0.019 0.01 .555
  1. aUnadjusted
  2. bAdjusted for age, sex, diabetes nephropathy, BMI, SBP, vascular access, duration of nephrologists care, and CTR
  3. cAdjusted for variables in model 2 plus albumin and CRP
  4. dAdjusted for variables in model 2 plus total cholesterol, triglyceride, high lipoprotein cholesterol, and glucose
  5. eAdjusted for variables in model 2 plus calcium, phosphate, and intact-PTH
  6. fAdjusted for variables in model 2 plus Fe, TIBC, ferritin, and usage of iron medication
  7. gAdjusted for variables in model 2 plus usage of angiotensin-converting enzyme inhibitors, angiotensin-II receptor blockers, and AST-120
  8. hAdjusted for all variables from model 2 to 7